Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

Simona Di Giambenedetto, Roberta Gagliardini, Barbara Rossetti, Claudia Bianco, Manuela Colafigli, Andrea De Luca, S Rusconi, R Prinapori, D Francisci, A Fantauzzi, G Orofino, F Vignale

Risultato della ricerca: Contributo in rivistaContributo a convegnopeer review

Abstract

HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.
Lingua originaleEnglish
pagine (da-a)19818-19818
Numero di pagine1
RivistaJournal of the International AIDS Society
Volume17
DOI
Stato di pubblicazionePubblicato - 2014
EventoHIV Drug Therapy Glasgow Congress 2014 - Glasgow
Durata: 2 nov 20146 nov 2014

Keywords

  • HCV
  • HIV
  • Risk factor
  • liver
  • therapy

Fingerprint

Entra nei temi di ricerca di 'Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study'. Insieme formano una fingerprint unica.

Cita questo